The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Category: Infectious Disease & AMR

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Infectious Disease & AMR

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

SEP 15, 2026
Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
Editor's Choice

Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment

APR 8, 2026
Ferring Presents New Data Analyses for REBYOTA®
Infectious Disease & AMR

Ferring Presents New Data Analyses for REBYOTA®

NOV 4, 2025
Phagos Raises €25m Series A
Animal Health

Phagos Raises €25m Series A

OCT 10, 2025
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner
Finance

Microba Delivers Landmark IBD Results & Signs Major Gastro Partner

APR 29, 2025
Synthetic microbiome therapy suppresses bacterial infection without antibiotics
Infectious Disease & AMR

Synthetic microbiome therapy suppresses bacterial infection without antibiotics

MAR 5, 2025
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
Finance

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

FEB 26, 2025
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Clinical & Manufacturing

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

JAN 27, 2025
Changes in microbiome predict risk for sexually transmitted disease
Infectious Disease & AMR

Changes in microbiome predict risk for sexually transmitted disease

JAN 22, 2025
Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics
Biotics and Supplements

Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics

DEC 17, 2024
SNIPR Biome receives up to €20 million European backing to advance therapies AMR
Finance

SNIPR Biome receives up to €20 million European backing to advance therapies AMR

DEC 10, 2024